查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493197

美国骨关节炎注射市场规模、份额和趋势分析报告：按註射剂类型、解剖结构、最终用途和细分市场预测，2024-2030 年

U.S. Osteoarthritis Injectables Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10个工作天内

价格

美国骨关节炎注射剂市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国骨关节炎注射市场预计将达到63亿美元，2024年至2030年复合年增长率为6.8%。

这个市场主要是由骨关节炎盛行率的增加和对个人化医疗的高需求所推动的。此外，製药公司以及研究和学术机构也参与了该国针对 OA 的个人化和细胞治疗方法的开发。例如，2023 年 5 月，UCI Health 宣布进行 IMMO1-STEM 的首次人体临床试验，这是一种基于细胞的注射疗法，用于治疗轻度至中度膝骨关节炎患者的肌肉萎缩。

老年人口的增加（更容易患膝骨关节炎）正在推动市场成长。根据 NCBI 2023 年 5 月的报告，由于快速老化和肥胖，预计到 2030 年，骨关节炎患者人数将增加一倍以上，达到 6,700 万人。此外，超过 50% 的 OA 病例预计发生在 65 岁及以上的年龄层。根据 2024 年 3 月 CDC 支持的 OAAA 研究，约 45% 的 OA 患者年龄超过 65 岁，所有病例中 88% 发生在 45 岁及以上年龄层。在日本，膝关节 OA 的年发生率在 55 岁至 64 岁之间最高。人口老化的高风险会降低工作效率并增加国家的疾病负担，进而影响整体生产力。

为了控制骨关节炎的症状并防止其结构性进展，各大製药公司和研究机构正在积极从事新药的研发活动，特别是缓解疾病的疗法。例如，2024 年 1 月，BioSenic 宣布计划在 2024 年国际骨关节炎协会 (OARSI) 世界大会上共用JTA-004 3 期研究的事后分析资料。 JTA-004是一种创新的膝关节骨关节炎治疗药物，这项研究表明，单次注射该临床实验药物对于膝关节骨关节炎的严重发炎亚型是安全有效的。

此外，研究和学术机构也参与了骨关节炎新治疗方法的发展。例如，根据 2023 年 3 月的《科学转化医学》报告 GP130，一种临床实验药物可以消除发炎并控制疼痛和僵硬。该药物现在将在早期临床试验中进行测试。此外，2021 年 12 月，Kolon TissueGene, Inc. 宣布美国FDA 已批准启动 TG-C 治疗髋关节 OA 的 2 期临床试验。该试验将评估研究期间疼痛和生活品质的改善。

美国骨关节炎注射市场报告亮点

  • 2023年，玻尿酸（HA）注射领域主导美国市场。 HA 注射疗法治疗骨关节炎的最新进展引起了人们对基于 HA 的水凝胶疗法的关注。
  • 2023年，膝骨关节炎细分市场占最大市场。这种疾病的日益流行预计将增加老年族群中预防和治疗膝骨关节炎的需求，以提高老年人口的生活品质并降低残疾率。
  • 零售药房领域预计在预测期内复合年增长率最快。零售药局充当製造商和医疗保健提供者之间的中间人，大量购买膝骨关节炎注射并储存起来，直到需要为止。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国骨关节炎注射市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国骨关节炎注射剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析

第四章美国骨关节炎注射市场：注射类型估算及趋势分析

  • 美国骨关节炎注射剂市场：注射型仪表板
  • 美国骨关节炎注射市场：注射品种波动分析
  • 按註入类型分類的收益
  • 玻尿酸注射
  • 皮质类固醇注射
  • 富血小板血浆（PRP）注射
  • 胎盘组织基质 (PTM) 注射
  • 乙酰水杨酸（ASA）注射液
  • 其他的

第五章美国骨关节炎注射市场：解剖估算与趋势分析

  • 美国骨关节炎注射市场：解剖仪表板
  • 美国骨关节炎注射市场：解剖变异分析
  • 解剖学、收益
  • 膝骨关节炎
  • 髋骨关节炎
  • 手骨关节炎
  • 其他的

第六章美国骨关节炎注射市场：最终用途估计与趋势分析

  • 美国骨关节炎注射剂市场：最终用途仪表板
  • 美国骨关节炎注射剂市场：最终用途变化分析
  • 按最终用途分類的收益
  • 医院药房
  • 零售药房
  • 其他的

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
  • 公司简介
    • Anika Therapeutics, Inc.
    • Bioventus.
    • Ferring Pharmaceuticals Inc.
    • Sanofi SA
    • Flexion Therapeutics, Inc.
    • Zimmer Biomet
    • Arthrex, Inc.
    • Royal Biologics
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-264-3

U.S. Osteoarthritis Injectables Market Growth & Trends:

The U.S. osteoarthritis injectables market size is anticipated to reach USD 6.30 billion by 2030 and is expected to expand at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing prevalence of osteoarthritis and high demand for personalized medicine. Moreover, pharmaceutical companies and research & academic institutes are involved in the development of personalized treatment and cell-based therapies for OA in the country. For instance, in May 2023, UCI Health announced the first-in-human clinical trial of its IMMO1-STEM, a cell-derived injectable treatment, to target muscle atrophy in patients with mild to moderate knee osteoarthritis.

Growing geriatric population susceptible to osteoarthritis fuels the growth of the market. According to the NCBI report in May 2023, a rapidly aging population coupled with obesity is expected to more than double the number of people suffering from OA to 67 million by 2030.Moreover, it is expected that more than 50% of OA cases are expected to occur in the age group of 65 and above.According to an OAAA study supported by CDC in March 2024, around 45% of people having OA are 65 & above and 88% of the total cases occur in the age group of 45 & above. The annual incidence of knee OA is highest among people aged 55 to 64 in the country. Such a high risk for geriatric population is affecting overall productivity by reducing work efficiency and increasing the disease burden in the country.

Increase in R&D activities for injectable drug development is boosting the market growth.To manage OA symptoms and prevent its structural progression, key pharmaceutical companies and research institutes are actively involved in R&D activities for the development of novel drugs, especially disease-modifying OA drugs. For instance, in January 2024, BioSenic announced its plans to share the data of post hoc analysis of the phase 3 study of JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024. JTA-004 is an innovative IA treatment for knee OA, and the study showed that a single injection of an investigational drug is safe and effective for the treatment of severe inflammatory subtypes of knee OA.

Furthermore, research and academic institutes are involved in the development of novel treatment options for OA. For instance, in March 2023, according to Science Translational Medicine report GP130, an investigational drug can disrupt inflammation and manage pain & stiffness. The drug will be tested in the upcoming initial phases of clinical trials. Moreover, in December 2021, Kolon TissueGene, Inc. announced that the U.S. FDA allowed it to initiate a Phase 2 clinical trial of TG-C in OA of the hip. The study will assess the pain and quality-of-life improvements during the investigation period.

U.S. Osteoarthritis Injectables Market Report Highlights:

  • In 2023, Hyaluronic Acid (HA) injections segment dominated the U.S. market, owing to recent advancements in HA injection therapy for osteoarthritis focus on HA-based hydrogel therapeutics.
  • Knee osteoarthritis segment held the largest share of the market in 2023.The rising prevalence of the condition is expected to boost the need for the prevention and treatment of knee osteoarthritis in the older population to improve quality of life and decrease disability rates in the elderly population.
  • The retail pharmacies segment is anticipated to witness the fastest CAGR over the forecast period. Retail pharmacies serve as intermediaries between manufacturers and healthcare providers, purchasing osteoarthritis injectables in bulk and storing them until requested.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Injection Type
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Injection Type
    • 2.2.2. End-use
  • 2.3. Competitive Insights

Chapter 3. U.S. Osteoarthritis Injectables Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of osteoarthritis
      • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
      • 3.2.1.3. Increase in R&D activities for injectable drug development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adoption of other treatment options
      • 3.2.2.2. High cost of treatment
  • 3.3. U.S. Osteoarthritis Injectables Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Pricing Analysis
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis

  • 4.1. U.S. Osteoarthritis Injectables Market: Injection Type Dashboard
  • 4.2. U.S. Osteoarthritis Injectables Market: Injection Type Movement Analysis
  • 4.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Injection Type, Revenue (USD Million)
  • 4.4. Hyaluronic Acid Injections
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Corticosteroid Injections
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Platelet-rich Plasma (PRP) Injections
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Placental Tissue Matrix (PTM) Injections
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Acetylsalicylic Acid (ASA) Injections
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis

  • 5.1. U.S. Osteoarthritis Injectables Market: Anatomy Dashboard
  • 5.2. U.S. Osteoarthritis Injectables Market: Anatomy Movement Analysis
  • 5.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Anatomy, Revenue (USD Million)
  • 5.4. Knee Osteoarthritis
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Hip Osteoarthritis
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Hand Osteoarthritis
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis

  • 6.1. U.S. Osteoarthritis Injectables Market: End-use Dashboard
  • 6.2. U.S. Osteoarthritis Injectables Market: End-use Movement Analysis
  • 6.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By End-use, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Anika Therapeutics, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bioventus.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Ferring Pharmaceuticals Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Sanofi S.A.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Flexion Therapeutics, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Zimmer Biomet
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Arthrex, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Royal Biologics
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Teva Pharmaceutical Industries Ltd.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Pipeline analysis, osteoarthritis injectables
  • Table 4 Pricing of key injectable drugs/therapies
  • Table 5 U.S. osteoarthritis injectables market revenue estimates and forecast, by injection type, 2018 - 2030 (USD Million)
  • Table 6 U.S. osteoarthritis injectables market revenue estimates and forecast, by anatomy, 2018 - 2030 (USD Million)
  • Table 7 U.S. osteoarthritis injectables market revenue estimates and forecast, by end use, 2018 - 2030 (USD Million)
  • Table 8 Company market share, 2023
  • Table 9 List of players adopting acquisition strategy
  • Table 10 Key companies undergoing partnership & collaborations.
  • Table 11 Key companies receiving approvals.
  • Table 12 Key companies undertaking other activities.

List of Figures

  • Fig. 1 U.S. osteoarthritis injectables market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Injection type and anatomy segment snapshot
  • Fig. 10 End-use segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market (USD billion)
  • Fig. 13 U.S. osteoarthritis injectables market dynamics
  • Fig. 14 Prevalence of osteoarthritis in the U.S., by type
  • Fig. 15 U.S. population aged 65 and above, by years (Million)
  • Fig. 16 U.S. pharmaceuticals registration details
  • Fig. 17 U.S. drug pricing
  • Fig. 18 U.S. osteoarthritis injectables market: PORTER's analysis
  • Fig. 19 U.S. osteoarthritis injectables market: PESTLE analysis
  • Fig. 20 U.S. osteoarthritis injectables market: Injection type outlook and key takeaways
  • Fig. 21 U.S. osteoarthritis injectables market: Injection type movement analysis
  • Fig. 22 Corticosteroid injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Hyaluronic acid injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Platelet-rich Plasma (PRP) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Placental Tissue Matrix (PTM) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Acetylsalicylic Acid (ASA) injections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. osteoarthritis injectables market: Anatomy outlook and key takeaways
  • Fig. 29 U.S. osteoarthritis injectables market: Anatomy movement analysis
  • Fig. 30 Knee osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Hip osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Hand osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. osteoarthritis injectables market: End-use outlook and key takeaways
  • Fig. 35 U.S. osteoarthritis injectables market: End-use movement analysis
  • Fig. 36 Hospitals pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)